ForteBio® Announces New Octet® RED System for Drug Candidate Characterization and Selection
Product News Apr 04, 2008
ForteBio®, Inc. has announced the launch of the Octet® RED System, for label-free, real-time kinetic analysis of drug compounds.
The Company claims that the new system brings unparalleled ease-of-use, sensitivity, throughput and affordability to the analysis of small molecules, peptides and proteins for research, development and bioprocessing.
The Octet RED System will debut at the Society for Biomolecular Sciences's 14th Annual Conference and Exhibition to be held April 6-10, 2008, in St. Louis, Missouri (Booth #1112).
"In drug discovery and development, kinetic analysis of drug compounds has been limited to highly trained specialists using expensive, complex and time- consuming instrumentation," said Joseph D. Keegan, Ph.D., president and chief executive officer of ForteBio.
"The Octet RED System provides higher sensitivity to enable label-free detection and analysis of low molecular weight molecules that can be performed easily, quickly and inexpensively and with higher throughput, as a routine laboratory procedure by any user, including non-experts," Dr. Keegan added.
The degree to which a drug compound binds to a therapeutic target helps predict a drug candidate's potency and effectiveness, and is a significant component of drug discovery and lead optimization. A label-free method of analysis is increasingly preferred because it avoids label interference with the binding activities of the therapeutic target.
The Octet RED System is based on ForteBio's proprietary BioLayer Interferometry (BLI) technology, in which optical biosensors measure multiple interactions in parallel, without the use of chemical labeling. The Octet RED System's data acquisition capabilities enable analysis of low molecular weight molecules that exhibit fast kinetics, which is critical for comprehensive kinetic characterization of drug candidates.
"Label-free interaction analysis is a growing area for advancing leads in drug discovery and research," said Dr. Keegan. "Now, by enabling pharmaceutical and biotechnology companies to conduct this analysis earlier in the process, in a faster and more affordable manner, the Octet RED System will help these companies accelerate drug development by validating screening campaign hits."